BRPI0509881A - combinação terapêutica para tratamento da doença de alzheimer - Google Patents

combinação terapêutica para tratamento da doença de alzheimer

Info

Publication number
BRPI0509881A
BRPI0509881A BRPI0509881-5A BRPI0509881A BRPI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A BR PI0509881 A BRPI0509881 A BR PI0509881A
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
treatment
therapeutic combination
treating alzheimer
Prior art date
Application number
BRPI0509881-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregg H Larson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0509881A publication Critical patent/BRPI0509881A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BRPI0509881-5A 2004-04-14 2005-04-04 combinação terapêutica para tratamento da doença de alzheimer BRPI0509881A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
BRPI0509881A true BRPI0509881A (pt) 2007-10-16

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509881-5A BRPI0509881A (pt) 2004-04-14 2005-04-04 combinação terapêutica para tratamento da doença de alzheimer

Country Status (14)

Country Link
EP (1) EP1737539A1 (no)
JP (1) JP2007532624A (no)
KR (1) KR20060133008A (no)
CN (1) CN1960781A (no)
AU (1) AU2005232447A1 (no)
BR (1) BRPI0509881A (no)
CA (1) CA2562069A1 (no)
IL (1) IL178120A0 (no)
MX (1) MXPA06011969A (no)
NO (1) NO20065196L (no)
RU (1) RU2006136361A (no)
TW (1) TW200533341A (no)
WO (1) WO2005099823A1 (no)
ZA (1) ZA200608239B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
CA3012415C (en) * 2016-02-11 2024-03-12 Sigmathera Sas Igmesine for use in the treatment of neurodegenerative diseases
MX2021015266A (es) * 2019-06-14 2022-01-18 Joshua O Atiba Composicion farmaceutica triple para infecciones proteinaceas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
ATE331523T1 (de) * 2002-04-02 2006-07-15 Janssen Pharmaceutica Nv Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
CN1791423A (zh) * 2003-03-19 2006-06-21 阿雷斯贸易股份有限公司 阿尔茨海默病的治疗
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
AU2005232447A1 (en) 2005-10-27
IL178120A0 (en) 2006-12-31
CN1960781A (zh) 2007-05-09
ZA200608239B (en) 2008-06-25
MXPA06011969A (es) 2006-12-15
CA2562069A1 (en) 2005-10-27
NO20065196L (no) 2007-01-03
KR20060133008A (ko) 2006-12-22
EP1737539A1 (en) 2007-01-03
WO2005099823A1 (en) 2005-10-27
JP2007532624A (ja) 2007-11-15
TW200533341A (en) 2005-10-16
RU2006136361A (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
EA200901373A1 (ru) Аминогетероциклические соединения
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
BRPI0514303A (pt) composição farmacêutica e método para tratar distúrbios neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/445 (2006.01), A61P 25/28 (2006.01), A61K